News
Cellectis to present Q1 2024 financial results on May 28, 2024
Cellectis Inc.
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop cells life-saving and gene therapies, announced today that it will report financial results for the first quarter of 2024, ending March 31, 2024, on Tuesday, May 28, 2024, after the US market closes.
The publication will be followed by an investor conference call and webcast on Wednesday, May 29, 2024, at 8am ET/2pm CET. The conference call will include the Company’s first quarter results and an update on business activities. The call details are as follows:
Dial information:
Domestic: 1-877-451-6152
International: 1-201-389-0879
Conference ID: 13746795
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1672725&tp_key=f83e7ab481
About Cellectis
Cellectis is a clinical-stage biotechnology company leveraging its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach to CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf gene-edited CAR T cells to treat cancer patients and a platform for therapeutic gene editing in hemopoietics. stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 24 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to leverage the power of the immune system. system for treating illnesses with unmet medical needs. Cellectis is headquartered in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS).
For more information about Cellectis, please contact:
Media Contact:
Pascalyne Wilson, Communications Director, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations Contacts:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Consultants, +1 617 430 7577
Attachment
